Holen Sie sich die Stockscreener-App
28.67
0.92%
0.26
Handel nachbörslich:
28.65
-0.02
-0.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$28.41
Offen:
$28.45
24-Stunden-Volumen:
27.18M
Relative Volume:
0.70
Marktkapitalisierung:
$163.41B
Einnahmen:
$63.32B
Nettoeinkommen (Verlust:
$7.52B
KGV:
21.98
EPS:
1.3043
Netto-Cashflow:
$9.48B
1W Leistung:
+3.65%
1M Leistung:
+0.35%
6M Leistung:
+5.10%
1J Leistung:
+21.48%
1-Tages-Spanne:
$28.17
$28.69
1-Wochen-Bereich:
$27.49
$28.85
52-Wochen-Spanne:
$23.61
$29.21
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
28.67 | 161.93B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,183.46 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.22 | 652.31B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.34 | 468.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.78 | 365.09B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
145.46 | 272.89B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? - Yahoo Finance
Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study - TipRanks
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
Pfizer stock reports a Q2 earnings beat at USD 28.43 - AD HOC NEWS
Pfizer stock heads into the open after a 0.82 percent gain - AD HOC NEWS
What Could Pfizer (PFE) Unlock From Faster FDA Reviews And Orphan Drug Growth? - Yahoo Finance
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost? - Yahoo Finance
Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans (NYSE:PFE) - Seeking Alpha
How AI Is Helping Match Patients to Clinical Trials Faster - Pfizer
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
Pfizer’s Japanese RSV Vaccine Study Wraps Up, Expanding Adult Market Potential - TipRanks
What Is Keeping Pfizer Inc. (NYSE:PFE) in the Healthcare Spotlight This September? - Kalkine Media
Pfizer Says It Removed Affected Batches From Market Amid Karnataka Fake Drug Probe - Medical Dialogues
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick? - TradingView
Pfizer stock gains as Q1 profit rises 6.6 percent - AD HOC NEWS
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - theglobeandmail.com
Pfizer Inc. : JP Morgan is Neutral - marketscreener.com
Pfizer (NYSE:PFE) Nears Breakout as Technical Strength and Setup Quality Reach Top Marks - ChartMill
Pfizer stock heads into the open after a 0.23 percent gain - AD HOC NEWS
Pfizer stock ends the day at USD 27.94 at the close - AD HOC NEWS
PFE Stock Quote Price and Forecast - CNN
Pfizer stock trades at INR 4,025.50 after India drug crackdown - AD HOC NEWS
What Is The Best Case For Pfizer Stock? - Yahoo Finance
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year - Yahoo Finance
Pfizer’s International Chief Just Explained How the Turnaround Actually Works. Here’s Where the Stock Could Go - TIKR.com
Why Is Pfizer (NYSE:PFE) Back in Focus as Wall Street Balances Growth and Defensive Demand? - Kalkine Media
Pfizer Inc. (PFE) stock price, news, quote and history - Yahoo Finance UK
Pfizer, Kraft, and UPS All Yield More Than 6%. Which of These Dividend Stocks Is the Safest Option Today? - Yahoo Finance
Pfizer stock holds near USD 28 as new products gain ground - AD HOC NEWS
Can Pfizer (NYSE:PFE) turn pipeline renewal and commercial launches into a stronger market story? - Kalkine Media
Pfizer Inc. stock heads into the open after a 0.23 percent gain - AD HOC NEWS
What Is Keeping Pfizer (NYSE:PFE) in S&P 500 Market Focus Today? - Kalkine Media
Party General Secretary and President visits US pharmaceutical giant Pfizer - VOV.VN
Is Pfizer (PFE) Getting Too Pricey After Its 24% Rise? - simplywall.st
Pfizer: A Quietly Outperforming High-Dividend Idea, Pipeline On Watch (Upgrade) - Seeking Alpha
Zuckerberg, Bourla among CEOs to attend Trump's state dinner for Xi, sources say - Reuters
Pfizer stock rises 0.23 percent at the close - AD HOC NEWS
Pfizer: A Conservative Valuation Leaves Room For A Post-LOE Re-Rating (NYSE:PFE) - Seeking Alpha
Pfizer: Stagnant Dividends At Rich YieldsIncome Before Appreciation (NYSE:PFE) - Seeking Alpha
Pfizer: The Market Won't Pay For 2029 Until It CanDowngrading To Hold (NYSE:PFE) - Seeking Alpha
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts - Business Wire
Pfizer CEO Bourla plans to attend White House state dinner for China's Xi, source says - marketscreener.com
What's Driving Pfizer's Move in Healthcare Stocks This Week? - Kalkine Media
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures wi - benzinga.com
Transcript : Pfizer Inc. Presents at U.S. All Stars Conference, Sep-22-2026 10:50 AM - marketscreener.com
Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline - Yahoo Finance
AbbVie vs. Pfizer: Which is the Better Dividend Investment? - Intellectia AI
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? - Yahoo Finance
Pfizer stock holds near USD 28 as earnings date approaches - AD HOC NEWS
Pfizer Inc. - Britannica
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):